Early in 2016, another study confirmed that different breast cancer subtypes may have various pharmacological reactions against BET inhibitors, thereby reflecting the distinctive contribution of BET signaling pathways in different breast cancer subtypes [61]. This evidence concerns the gene DNER and breast cancer.